All In Biotech

Drug Trial Radar · NCT01147627

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial

Last checked: Nov 20, 2026Latest source record: Aug 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

Aug 2010

Primary completion

Aug 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company; Amylin Pharmaceuticals, LLC.; Ministry of Health, China
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2 diabetic patients.

Conditions

  • Diabetes Mellitus, Type 2
  • Newly Diagnosed

Interventions

  • exenatide injectionDrug

    Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.

  • Mixed Protamine Zinc Recombinant Human Insulin Lispro 25RDrug

    Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.

  • PioglitazoneDrug

    Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the Comparison Between Treatment Groups of the Changes From Baseline in HbA1c at 48 WeeksTime frame: 48 weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • The Military General Hospital of Beijing PLA

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Qingyuan People's hospital

    Qingyuan, Guangdong, China

  • The first Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Affiliated hospital of Guangdong medical college

    Zhanjiang, Guangdong, China

  • The first affiliated hospital of Guangxi Medical College

    Nanning, Guangxi, China

  • The Affiliated Hospital of Guiyang Medical College

    Guiyang, Guizhou, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Second Xiangya Hospital of Central-south University

    Changsha, Hunan, China

  • The Affiliated Hospital of Inner Mangolia Medical College

    Hohhot, Inner Mongolia, China

  • Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Zhongda Hospital of Southeast University

    Nanjing, Jiangsu, China

  • China Medical University

    Shenyang, Liaoning, China

  • Xijing Hospital of The Fourth Military Medical University

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Kunming Medical College

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.